Cheng Hao
Partner @ WisdoMont Asset Management
Cheng Hao is a Series A investor at WisdoMont Asset Management focused on Biotechnology and Health Care. Cheng Hao is the managing director of Shengshan Capital
- Total investments:
- 9
- Last investment:
- Lead investor:
- 78%
Last updated:
For AI agents: llms.txt
Industries Cheng Hao invests in
Stages Cheng Hao invests in
Countries Cheng Hao invests in
Investment Focus
Industry
- Biotechnology 5 (56%)
- Health Care 4 (44%)
- Biopharma 3 (33%)
- Pharmaceutical 3 (33%)
- Medical 2 (22%)
Stage
- Series A 4 (44%)
- Series B 2 (22%)
- Seed 1 (11%)
- Series C 1 (11%)
Country
- China 7 (78%)
- Switzerland 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Leman Biotech
|
Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | $28.8M / Series A / Jan 26, 2026 | |
|
Leman Biotech
|
Leman Biotech is a biotech company that is engaged in development of cancer immunotherapies. | Series A / Nov 12, 2024 | |
X-Imaging
|
X-Imaging provides full-process automation and intelligent, comprehensive solutions. They are molecules to cells for biochemistry, medical medicine, and safety inspection and testing. The product range covers food safety, drug safety, life science fields, and intelligent robot workstation systems. | $13.9M / Series B / Dec 11, 2023 | |
Hanhong Technology
|
Hanhong Technology is a biomedicine firm that specializes in drug research, innovative synthetic biology, and pharmaceutical intermediates. | $13.9M / Series A / Dec 11, 2023 | |
Euregen Biopharma
|
Euregen Biopharma is a pharmaceutical company that specializes in the innovation and development of synthetic lethal drugs for tumors. | Seed / Oct 20, 2023 | |
Changjin Biotechnology
|
Changjin Biotechnology engages in the research, development, and industrialization of microbial synthetic proteins. | Series A / Jun 06, 2023 | |
Mainstream Biotech
|
Mainstream Bio is a biotechnology company grounded in research, specializing in the development of innovative peptide therapeutics 2.0. | $13.8M / Series A / Nov 09, 2022 | |
Konfoong Biotech International
|
KFBIO’s uses big data, cloud computing and AI to quickly and reliably scan and digitise images, making them easier to share with experts to improve the speed and accuracy of diagnosis. | $14.9M / Series C / Jul 12, 2022 | |
Resproly
|
Resproly is a research and development, production and sales of formula and equipment for respiratory inhalation. An integrated enterprise that focuses on multiple clinically demanding treatment areas such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Diabetes, and Parkinson's Disease. | Series B / Apr 30, 2022 |
Co-Investors
About WisdoMont Asset Management
WisdoMont Asset Management is a Shengshan Assets is an excellent venture capital and private equity fund management company in China. Shengshan Assets closely monitors investment opportunities in medical health and smart big data under the trend of consumption upgrading.
WisdoMont Asset Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Cheng Hao
Partner
|
|||
Ganshi Xiong
Founding Partner
|
|||
Shen Qiang
Managing Partner
|
|||
2 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Cheng Hao invest in?
Cheng Hao invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Cheng Hao last invest?
The most recent investment recorded for Cheng Hao closed in Jan 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
